Company Overview
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images. Spectral AI, Inc. is headquartered in Dallas, Texas.
Why Investors Should Care
Generates a return on equity of 132.2%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $19.65M (-33.6% YoY); net profit $-7.57M.
- Trailing 12 Months Year-on-year growth — revenue -30.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -8.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -8.16% |
| 1 Year: | -30.40% |
Stock Price Performance
| 1 Year: | -23.88% |
| 6 Months: | +14.18% |
| 3 Months: | -12.97% |
| 1 Month: | -8.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 132.2%.
CONS
- Revenue declined at -8.2% CAGR over 5 years.
- Trading 39.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDAI Spectral AI, Inc. PHARMA | 1.61 | -5.03 | $51.82M | 0.00% | - | 132.20% | -8.16% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 7.04M | 5.08M | 4.25M | 3.44M | 6.33M | 7.48M | 8.17M | 6.71M | 5.07M | 3.79M | 3.99M |
| Gross Profit | - | - | - | - | - | 3.23M | 2.18M | 1.79M | 1.47M | 2.94M | 3.31M | 3.67M | 3.17M | 2.29M | 1.62M | 2.03M |
| Operating Income | -157.82K | -287.04K | -1.19M | -465.12K | -248.72K | -251.00K | -2.90M | -2.99M | -4.17M | -2.14M | -2.44M | -886.00K | -896.00K | -2.12M | -3.34M | -1.97M |
| Net Income | 3.22M | -2.90M | 2.23M | -528.00K | -265.00K | -380.00K | -3.61M | -3.07M | -10.63M | -3.21M | -2.86M | -1.50M | 2.90M | -7.97M | -3.55M | -3.41M |
| Diluted EPS | - | - | - | - | - | -0.03 | -0.27 | -0.23 | -0.77 | -0.19 | -0.16 | -0.08 | 0.11 | -0.31 | -0.13 | -0.11 |
| R&D Expense | - | - | - | - | - | - | 4.00M | - | - | 4.30M | - | - | 3.60M | - | - | 2.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 25.37M | 18.06M | 29.58M | 19.65M |
| Gross Profit | - | 10.84M | 7.88M | 13.27M | 8.93M |
| Operating Income | -3.42M | -2.65M | -12.98M | -6.58M | -8.60M |
| Net Income | -2.15M | -2.91M | -20.85M | -15.16M | -7.57M |
| Diluted EPS | - | -0.22 | -1.48 | -0.85 | -0.29 |
| R&D Expense | - | 16.50M | 15.10M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 164.90K | 254.11M | 18.72M | 10.69M | 12.10M | 21.41M |
| Total Equity | 24.32K | 13.75M | 12.00M | -2.15M | -7.25M | -5.73M |
| Cash & Equivalents | - | 769.43K | 14.17M | 4.79M | 5.20M | 15.40M |
| Long Term Debt | - | - | - | - | - | 5.54M |
| Total Liabilities | 140.57K | 21.93M | 6.72M | 12.40M | 19.35M | 27.13M |
| Current Liabilities | 140.57K | 2.94M | 6.37M | 12.40M | 17.64M | 20.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.16M | -13.24M | -9.20M | -9.92M |
| Investing Cash Flow | -7.00K | 0 | - | - | - |
| Financing Cash Flow | - | -785.00K | 3.84M | 9.57M | 20.12M |
| Capital Expenditure | -7.00K | - | - | - | - |
| Free Cash Flow | - | -1.16M | -13.24M | -9.20M | -9.92M |
| Net Change in Cash | - | -1.95M | -9.40M | 376.00K | 10.20M |
| Share Buybacks | 0 | 250.52M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 42.7% | 43.6% | 44.9% | 45.4% |
| Operating Margin % | - | -10.4% | -71.9% | -22.3% | -43.8% |
| Net Margin % | - | -11.5% | -115.5% | -51.2% | -38.5% |
| ROE % | -15.6% | -24.3% | 970.4% | 209.0% | 132.2% |
| ROCE % | -1.4% | -21.4% | 759.7% | 118.6% | -1,104.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.09% | 994.41K | $1.63M |
| 2 | Highlander Partners, L.P. | 2.80% | 900.00K | $1.48M |
| 3 | Marshall Wace LLP | 2.57% | 827.45K | $1.36M |
| 4 | Bridgeway Capital Management, LLC | 0.89% | 287.00K | $470.68K |
| 5 | UBS Group AG | 0.70% | 225.82K | $370.35K |
| 6 | Jane Street Group, LLC | 0.70% | 226.32K | $371.16K |
| 7 | Geode Capital Management, LLC | 0.69% | 222.59K | $365.06K |
| 8 | Blackrock Inc. | 0.50% | 161.78K | $265.31K |
| 9 | LPL Financial LLC | 0.50% | 160.70K | $263.55K |
| 10 | Vanguard Fiduciary Trust Co | 0.44% | 142.66K | $233.97K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDAI
Analyst Estimates: Here's What Brokers Think Of Spectral AI, Inc. (NASDAQ:MDAI) After Its First-Quarter Report - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOV09lV2QxbW1nLV9VdDVwd21jcDVHS2JISEpCM0RCV1cwdVN4bVV3dU1aVW1pNEFLR1htWHhwM2x1Y25HdHgwTFE0dWRvT1ktNXhXbWJzLTd5S0dKS0FhZUhGd2diUURwWVMzSFUwdWhnVElWLWxLczRtb0lLR2lQVlFhalNJV0hLOFNuZ0…
MDAI: The Lull Between Approval and First Sale - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQRHpkU21fOFQ2VExKS25EVHdubkNuR19XdkZmOFRHN01BVEI5cUxucS1CdzZxclRhV0xUaUZHNFdTbmdZYk8xWnJTN19fVWlkSmQyTW9sVDE2bU9OWExpb25wQmZtY3hvamtaLXBZRHV4Mi1WQ3Jia2sxOXowNi1yLVZWMElzc3dwaGlSLX…
MDAI Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9rSU9odHZFTTRZTEtwZEhlZzFzZXNzdmdmaWZ4QlR3UFI0ZVYwVFkySVZidVJzNFVZYVUyMUs5WU1uMXl4c2ZNenNWem9XV2I0T1BweURWSGxTRVJlU2ZQN18yZC1fNllxZ1oyTFF6T05sc2hyd0ZPdXFn?oc=5" target="_blank">MDA…
SPECTRAL AI ($MDAI) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQTEFWb2JUWTA1OFg0M0U5c3lEV0w0ckU2dnJKYjgyTnViZ1RHczlVX2F3eC1NcDRUYl9lMDBHeERFOVpzTzY1MmwxTUg1VUx2Y1plUnZGeENQU1VtNm94OF9mOTRxU1JZTVQxbUI2UTlBT2tzQjZQTXBPMWFoRi1rYk02Y3hsX0w5Nkt6V2…
US backs burn-diagnosis AI: Spectral AI wins $31.7M boost - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQ3FmdERKQ29xQk55T0lkeGdIeFlfdXJFUWhGeEFydnZoek8tampsTm1IQ1A2T2tjM0NWUldsXzdNWWE4cWtreXlmMWlXd016NV84aVFybk0xRmoyb2hQazg4TU9ZZWNjUmtUY05aOFh0U2Q4MTVNZFU1ZE45cUl2NzNHaGF5VHVfYVNuUn…
MDAI - Spectral AI Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1ZYXRqMzI1bUFmWUFUaE5lRXByYTl2ZHZ2M2NaLUt5TVpaNzBlbTFoNkZJb2ZaMFJPM240Qkw3bVRGRmtRbEE?oc=5" target="_blank">MDAI - Spectral AI Inc Stock Price and Quote</a> <font color=…
MDAI — Frequently Asked Questions
What is the current share price of Spectral AI, Inc. (MDAI)?
As of 2026-09-19 21:16 PDT, Spectral AI, Inc. (MDAI) trades at $1.61 on NasdaqCM. Its 52-week range is $1.20 to $2.68.
What is the market capitalisation of MDAI?
Spectral AI, Inc. (MDAI) has a market capitalisation of $51.82M on NasdaqCM.
What is the P/E ratio of MDAI?
MDAI trades at a trailing price-to-earnings (P/E) ratio of -5.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -4.37.
What is the return on equity (ROE) of MDAI?
MDAI has a return on equity (ROE) of 132.20%.
Is MDAI a good stock to buy?
This page provides a data-driven analysis of Spectral AI, Inc. (MDAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.